Head-to-head · WeighScore
AskRx vs Boston Medical Group
The verdict
Boston Medical Group takes it — 61.9/100 to 55.8/100.
Boston Medical Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Boston Medical Group is an established medical group running a 12-week compounded GLP-1 weight-loss programme.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AskRx | Boston Medical Group |
|---|---|---|
| WeighScore | 55.8/100 | 61.9/100 |
| Grade | C | C |
| Scorecard rank | #429 | #279 |
| Semaglutide | $349/mo (all doses, brand-name) | $199/mo (starting strength, rising with dose, compounded) |
| Tirzepatide | $299/mo (2.5 mg dose, brand-name) | Not disclosed |
| Coverage | All 50 states | 7 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #429 · C
Strengths
- Prescribes only FDA-approved brand-name GLP-1s, no compounded drugs
- LegitScript approved and HIPAA compliant
- Board-certified physicians trained in obesity medicine
- Transparent dose-based pricing published on site
- Available in all 50 states
Where it loses points
- Cash-pay model; medication cost billed separately by the pharmacy
- Does not dispense medication itself, so fulfillment depends on third-party pharmacies
- No compounded lower-cost alternative offered
- Specific list of supported states is not published
Graded #279 · C
Strengths
- An established medical group with a defined 12-week programme rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
Where it loses points
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
- The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
- Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.